Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 78

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 78
---
O-B’s dopamine clearing mechanism, thus counteracting the mechanism that increases the body’s demand for dopamine.

| 40 |

Similar to its effect on overeating, SKNY-1 may have a similar effect on assisting with smoking cessation. At low doses, THCV can act as a CB1 antagonist to reduce the dopamine craving for nicotine, and as a partial agonist for CB2 Furthermore, while acting as a CB2 partial agonist, THCV helps stimulate CB2 to indirectly reduce the nicotine cravings by lowering inflammation and stress.

Potential Additional Application; Insulin Resistance

Studies have found that THCV may also influence metabolism, providing a potential additional application for this compound (Source: British Journal of Pharmacology ). By interacting with the ECS, particularly through the CB2 receptors, THCV might help in regulating blood sugar levels and reducing insulin resistance. This is particularly significant for individuals with obesity or type 2 diabetes, where insulin resistance is a common issue. In addition to appetite suppression, THCV has been linked to other metabolic benefits that could be relevant to obesity. It has demonstrated potential to improve glycemic control and reduce fasting plasma glucose levels in models of type 2 diabetes, a condition frequently associated with obesity. Some studies, including studies published in the Journal of Cannabis Research, also suggest it may help with dyslipidemia, a common obesity-related issue involving abnormal lipid levels in the blood . Human research is still limited but promising. A recent clinical trial involving obese adults found that daily administration of THCV combined with cannabidiol (“CBD”) via oral strips led to significant weight loss, reduced abdominal girth, lower systolic blood pressure, and improved cholesterol levels compared to a placebo group over 90 days. While these findings are encouraging, the study’s small sample size and the combination with CBD mean more research is needed to isolate THCV’s specific effects.

Also, this unique profile seems to be ideal to be able to treat the ensemble of factors related to smoking cessation and the associated weight gain, as the three components of the drug can work in concert to affect all the above parameters.

SKNY-1; a THCV Analog

SKNY-1 was synthetized as an analogue of THCV. THCV and SKNY-1 have similar effects, except that SKNY-1 has a five-membered ring, compared with THCV. The profile of SKNY-1 was evaluated in a Eurofin study, where it was confirmed as a potent CB2 partial agonist (IC50 at 70 nM